Skip to main content

Table 1 Mutational statuses of synchronous MSO and thyroid PTC cases reported in the literature

From: Synchronous thyroid cancer and malignant struma ovarii: concordant mutations and microRNA profile, discordant loss of heterozygosity loci

Patient Information

Tumor Size(s)

Thyroid PTC

Tumor Size

MSO

Molecular

Thyroid PTC

Molecular

MSO

Reference

35 y.o. female

1.7 cm

8.2 cm*

No BRAF mutation

No BRAF mutation

Capitão et al. (2017) [24]

62 y.o. female

0.8 cm

7.2 cm

HRAS Q61R

(38% mutant allele freq)

NRAS Q61R

(50% mutant allele freq)

Gomes-Lima et al. (2018) [3]

42 y.o. female

Microcarcinomas,

0.5 cm,

0.8 cm

13.5 cm*

No BRAF, KRAS, or RET/PTC mutation

No BRAF, KRAS, or RET/PTC mutation

Leong et al. (2013) [25]

47 y.o. female

0.7 cm

2.7 cm

KIT V530I

No BRAF or RAS mutation

KIT V530I

No BRAF or RAS mutation

Ma et al. (2016) [16]

44 y.o. female

0.05 cm

5 cm*

No BRAF mutation

No BRAF mutation

Marti et al. (2012) [22]

55 y.o. female

1.2 cm

1.5 cm

No BRAF mutation

No BRAF mutation

Middelbeek et al. (2017) [23]

32 y.o. female

0.6 cm

6.0 cm

No BRAF, RET/PTC, or TERT mutation

No BRAF, RET/PTC, or TERT mutation

Tzelepis (2019) [21]

42 y.o. female

0.3 cm,

0.15 cm

3 subcentimeter foci

BRAF V600E mutation

High-risk miRNA expression profile

BRAF V600E mutation

High-risk miRNA expression profile, LOH (1p, 3p, 5q, 9p, 17p and 22q)

Present Case

  1. Abbreviations: MSO - Malignant Struma Ovarii, PTC - Papillary Thyroid Carcinoma
  2. *Asterisk denotes size of ovary in the absence of PTC size data; Discordant LOH findings emphasized in bold